Clinical trial · Interventional
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Therapy for Unresectable Hepatocellular Carcinoma: a Multicenter, Randomized, Open-label Trial
NCT06360042CI-TRIAL-00076346recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adebrelimab plus Apatinib | Drug | — | UNRESOLVED |
| Adebrelimab plus Bevacizumab | Drug | — | UNRESOLVED |
| Camrelizumab plus Apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1
- description
- Adebrelimab（1200mg iv q3w） plus Apatinib(250mg po qd)
- interventionNames
- Drug: Adebrelimab plus Apatinib
- type
- EXPERIMENTAL
- label
- 2
- description
- Adebrelimab（1200mg iv q3w）plus Bevacizumab(15mg/kg iv q3w)
- interventionNames
- Drug: Adebrelimab plus Bevacizumab
- type
- EXPERIMENTAL
- label
- 3
- description
- Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC) * No prior systemic therapy for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed. * BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy * At least one measurable lesion per RECIST v1.1 * ECOG Performance Status of 0 or 1 * Child-Pugh class of A5 to B7 * Adequate organ function Exclusion Criteria: * Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously * Moderate-to-severe ascites with clinical symptoms * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Hypertension that can not be well controlled through antihypertensive drugs Factors to affect oral administration * History of hepatic encephalopathy * Previous or current presence of metastasis to central nervous system
References
Publications (0)
Data not yet available
No reference posted for this study.